Opioid Litigation • Controlled Substances • West Virginia • Pharmacy Compliance

West Virginia Opioid Recovery Effort Reportedly Fails Again After Appellate Revival

Law360 reports that Judge David Faber again ruled for three opioid distributors on November 18 after the Fourth Circuit vacated their earlier victory. The report describes a failure to prove diversion while the drugs were under the distributors’ control. The appellate court previously allowed West Virginia public-nuisance claims and money-funded abatement to proceed. This article distinguishes the reported outcome from the reviewed appellate record. The new district opinion and any separate judgment remain unreviewed.

By Toby C. “Chad” Frost • November 19, 2026
2 min read

The reported result

Law360 reported November 18 that Judge David Faber again ruled for AmerisourceBergen, Cardinal Health and McKesson after remand. Its public account describes insufficient proof that prescription opioids were diverted while under the distributors’ control.1

The litigation concerns Huntington and the Cabell County Commission’s claims against those distributors. The Fourth Circuit vacated the earlier defense judgment in October 2025 and returned the case for further proceedings.2

Source limitation: the November 18 district opinion and any separate judgment have not been independently reviewed for this article. The new result is attributed to Law360’s publicly available account. Its precise reasoning and current appeal status remain unverified.1

What the appellate record establishes

The Fourth Circuit held that opioid distribution could support a public-nuisance claim under West Virginia law. It required reconsideration of distributor duties, including scrutiny of individual orders and evidence concerning suspicious-order thresholds and unusually high prescribing.2

The court also required examination of foreseeable downstream conduct in assessing causation. It permitted money-funded abatement as a potential remedy. The approximately $2.5 billion program was requested relief, rather than an award, and liability remained to be determined.2

Operational analysis

Chad’s analysis: the reported result raises a focused question about how the trial court applied the appellate instructions. The complete opinion is needed to determine whether the outcome turns on a factual shortfall or on a disputed interpretation of control and causation. The existence of a public-health crisis, the availability of a legal claim and proof against particular defendants are separate questions.

Chad’s analysis: pharmacy leaders can use this litigation to examine the evidentiary quality of their own controls. A written policy has limited explanatory value without records showing what a warning triggered, who reviewed it and why the resulting decision was made. The article will require a source-based update when the new opinion and judgment can be reviewed.

Source notes

  1. Rae Ann Varona, Opioid Sellers Prevail Again in W. Va. After 4th Circ. Reversal, Law360 (Nov. 18, 2026, 11:43 PM EST) (public article summary; attached district opinion not independently reviewed).
  2. City of Huntington v. AmerisourceBergen Drug Corp., Nos. 22-1819 & 22-1822, slip op. at 5–6, 31–49 (4th Cir. Oct. 28, 2025) (vacating and remanding with instructions).